ABOUT US
History

History

  • 2021

    Technology evaluation for applicability of the technology-based listing scheme

    Signed a license agreement with Pierre Fabre for YBL-003press release

    Selected as an Excellent Corporate R&D Institute by the Ministry of Science and ICT

  • 2020

    Signed a license agreement with Pyxis Oncology for YBL-001 jointly developed with LegoChem Biosciencespress release

    Signed a license agreement with 3D Medicines (3D MED) for the China rights of YBL-013press release

    Signed a joint R&D agreement with NeoImmuneTech for YBL-018press release

    Signed a license agreement on antibody sequence with ViroCure for YBL-006, etc.press release

    Signed a license agreement on antibody sequence with GI Innovation for YBL-006, etc.press release

    Initiated Phase 1 clinical trials for YBL-006 in Korea, Australia and Thailand

    Registered a patent for ALiCE, a bispecific T cell engager platform, in the United States

    Received the IR52 Jang Young-shil Award for technological innovation (Minister of Science and ICT)

    Series D Funding: Raised 20 billion KRW

  • 2018

    Series C Funding: Raised 37.4 billion KRW

  • 2016

    Signed a joint R&D agreement with LegoChem Biosciences for YBL-001

    Signed a joint R&D agreement with HK inno.N for the discovery of 3 bispecific antibodies

    Series A/B Funding: Raised 15 billion KRW

  • 2015

    Seed Funding: Obtained 1 billion KRW

  • 2012

    Conducted joint research & development with Sanofi Aventis on a targeted antibody therapeutic for liver cancer (until 2014)

  • 2009

    Obtained Venture Business and Corporate R&D Institute certifications

  • 2007

    Establishment of Y-Biologics, Inc.